Managing Toxicities from Chronic Myeloid Leukemia Treatment

The panelists, Jorge Cortes, MD; Javier Pinilla-Ibarz, MD, PhD; Kevin Kelly, MD, PhD; David Snyder, MD, FACP; and Harry Erba, MD, PhD, comment on strategies to manage adverse events from tyrosine kinase inhibitor therapy used in the treatment of chronic myeloid leukemia.